Effect of concurrent CYP3A4 interacting medications on ibrutinib outcomes in patients with CLL.

e19514Background: Concurrent use of strong CYP3A4 inhibitors increases ibrutinib exposure 20-fold. Hence, use of strong CYP3A4 inhibitors/inducers is not recommended, and moderate inhibitors warran...